News

SanAir Technologies Laboratory Combines with Centek Laboratories

Expands Lab Testing Capabilities into Volatile Organic Compound (VOC) Air and Soil Gas Analysis

RICHMOND, Va., SanAir Technologies Laboratory, Inc. (SanAir) today announced its merger with Syracuse, NY-based Centek Laboratories, LLC (Centek), expanding its testing capabilities into VOCs using summa cannister and/or thermal desorption tubes technology (EPA Method TO-15 and TO-17) and analyzation of samples by GC/MS coupled with cryo-focusing or thermal desorption technology.

“Like SanAir, Centek is in the environmental laboratory analysis business but with additional capabilities not currently covered by our lab,” said SanAir President Sean P. McGlynn. “Centek has been a leader in vapor intrusion technology since they opened their doors in 2003, when they helped New York State’s Department of Health and its Department of Environmental Conservation change how samples were collected and tested, improving the technology to save money and increase detection limits in the ppb (part per billion) and ppt (part per trillion) detection range. They have brought that innovative, client-focused spirit to LEED®, WELL, IgCC Certification System; Biogas, Industrial Hygiene and Product Testing. We are excited to have Centek under the SanAir umbrella.”

The combined laboratories represent a total of 70 employees in Virginia, Ohio and New York.

Centek has been working in green and sustainable technology through indoor air quality (IAQ) testing since 2009 in conjunction with the U.S. Green Building Counsel (USGBC). Current testing programs include: LEED® IEQ Credit 3.2 2009 for New Construction and Major Renovations; LEED V4; LEED 4.1; WELL; and IgCC. Centek has been doing this testing throughout the United States, Canada and Mexico and is starting to open doors overseas.

Centek also has been testing BioGas reclamation systems in landfills and wastewater treatment plants (WWTP) throughout North America. The lab identifies a complete gas profile and determines the proper treatment processes needed to meet even the most stringent biogas specifications for use as a fuel.

“We are excited about the opportunities presented by our merger with SanAir,” said Russell Pellegrino, Centek’s Technical Director. “Our companies are similarly entrepreneurial but also grounded in our foundational principles of scientific accuracy and reliability in testing.

SanAir’s resources will help Centek continue to innovate and bring cost and time-efficient sampling solutions to our clients.”

The combination of the two laboratories caps a year of expansion for SanAir that includes moving into a new headquarters location in Greater Richmond (North Chesterfield) at the former Virginia Department of Emergency Management location, and the first fully operational and accredited year of industrial hemp and medical marijuana testing for the Company’s wholly-owned subsidiary, Sativa Testing Laboratories.

Read more here.

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near